Understanding uveitis: The impact of research on visual outcomes
Section snippets
The clinical importance of uveitis
Uveitis is an umbrella term used to describe a wide variety of inflammatory conditions occurring inside the eye. The term literally means inflammation of the uvea (Latin for grape), i.e. the iris, ciliary body and choroid, but adjacent structures such as the retina, optic nerve and sclera may also be involved. Uveitis accounts for 5–20% of legal blindness in both the United States and Europe, and perhaps as much as 25% of blindness in the developing world (Bodaghi et al., 2001, Rothova et al.,
Animal models in uveitis
Taking repeated ocular biopsies from patients is not ethically possible. Hence our understanding of the mechanisms of ocular damage in uveitis have come from using animal models (de Smet and Chan, 2001). Furthermore, histopathologic data derived from ocular samples provides data at only one timepoint, usually late in the course of the disease, whereas experimental models allow analysis during the entire disease process. Several animal species can be used to understand different aspects of the
Clinical, diagnostic and evaluation challenges in uveitis
Although uveitis encompasses a multitude of etiologies and disease phenotypes, its management relies on a set of pivotal factors: correct anatomical classification and etiologic diagnosis, identification of complications, assessment of disease activity, and the presence of any systemic disease associations (Guly and Forrester, 2010). Challenges remain in all of these areas, particularly as traditional biomedical thinking in uveitis care has led to an overemphasis on diagnostic testing. An
Challenges in disease management
Uveitis is a disease of varying phenotypes and visual prognosis: inflammation may be mild, moderate or severe; sight-affecting or sight-threatening complications may already be present at presentation; patients may be very symptomatic, particularly if there is severe anterior chamber involvement, macular edema with visual loss or vitritis with numerous floaters. These factors often drive clinical decision-making, but not all patients with uveitis require treatment. Patients with chronic
Predictors of disease activity
It would be ideal to identify patients who are in a high risk group for visual loss early in their disease process. This would enable a more aggressive approach to therapy to be taken, possibly preventing this loss of vision. It would also be useful to predict which patients are likely to be refractory to commonly used medication, to have more a severe inflammatory process, or to develop complications of uveitis such as glaucoma. Cytokine levels in blood and ocular fluids, intracellular
How can disease management be improved
Classical clinical trials rest on binary outcomes. This approach has endured the test of time and is favored by regulators, but it carries with it important ethical, economic and timing issues. For example, eyes in a control arm are at risk of permanent vision loss unless protocols are set up to include eyes with less severe disease even in the presence of rescue therapy. We group under the term uveitis a number of very different clinical entities whose only common denominator is the presence
References (311)
- et al.
Chemokines and gelatinases in the aqueous humor of patients with active uveitis
Am. J. Ophthalmol.
(2004) - et al.
The importance of visual function in the quality of life of children with uveitis
J. AAPOS
(2010) - et al.
Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study
Ophthalmology
(2001) - et al.
Vitrectomy in the treatment of uveitis
Am. J. Ophthalmol.
(2005) - et al.
Prevalence and genotypes of Toxoplasma gondii in feline faeces (oocysts) and meat from sheep, cattle and pigs in Switzerland
Vet. Parasitol.
(2011) - et al.
Chlorambucil and malignancy
Ophthalmology
(2010) - et al.
International uveitis study group recommendations for the evaluation of intraocular inflammatory disease
Am. J. Ophthalmol.
(1987) - et al.
Characteristics of uveitis presenting for the first time in the elderly
Ophthalmology
(1998) - et al.
Endotoxin-induced uveitis in the rat: observations on altered vascular permeability, clinical findings, and histology
Exp. Eye Res.
(1984) - et al.
Quality of life and health economic assessments of age-related macular degeneration
Surv. Ophthalmol.
(2007)
Childhood uveitis-young patients, old problems, new perspectives
J. AAPOS
Cellular immune responses of patients with uveitis to retinal antigens and their fragments
Am. J. Ophthalmol.
Regulation of ocular inflammation–what experimental and human studies have taught us
Prog. Retin. Eye Res.
Major retinal autoantigens remain stably expressed during all stages of spontaneous uveitis
Mol. Immunol.
Visual loss associated with pediatric uveitis in english primary and referral centers
Am. J. Ophthalmol.
The disease activity score and the EULAR response criteria
Rheum. Dis. Clin. North Am.
Retinal specific antigens and the immunopathogentic processes they provoke
Prog. Retin. Eye Res.
Refining clinical diagnosis with likelihood ratios
Lancet
Incidence and prevalence of uveitis in northern California; the Northern California epidemiology of uveitis study
Ophthalmology
Intraocular cytokine environment in active Behcet uveitis
Am. J. Ophthalmol.
The IFN-gamma +874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility. Mem. Inst
Oswaldo Cruz.
A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
Clin. Ophthalmol.
Cytokine polymorphism in noninfectious uveitis
Invest. Ophthalmol. Vis. Sci.
Grading quality of evidence and strength of recommendations
BMJ
Oxidative stress affects the junctional integrity of retinal pigment epithelial cells
Invest. Ophthalmol. Vis. Sci.
Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation
Br. J. Ophthalmol.
Monitoring treatment with biologics in non-infectious uveitis
Ophthalmologe
Unregistered visual impairment: is registration a failing system?
Br. J. Ophthalmol.
Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression
Ocul. Immunol. Inflamm.
Clinical aspects and diagnostic guidelines of ocular Behcet’s disease
Dev. Ophthalmol.
Uveitis in children and adolescents
Br. J. Ophthalmol.
Adaptive clinical trials: the promise and the caution
J. Clin. Oncol.
Adaptive assignment versus balanced randomization in clinical trials: a decision analysis
Stat. Med.
Bayesian Calculator
Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center
Medicine (Baltimore)
Correlation between morphologic features on spectral-domain optical coherence tomography and angiographic leakage patterns in macular edema
Retina
Experimental autoimmune anterior uveitis (EAAU): induction by melanin antigen and suppression by various treatments
Pigment Cell Res.
The burden of age-related macular degeneration: a value-based analysis
Curr. Opin. Ophthalmol.
Re-evaluation of biologic therapies in systemic lupus erythematosus
Curr. Opin. Rheumatol.
The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation
J. Rheumatol.
Emotional and social consequences of age-related low vision: a narrative review
Partial Sight Blindness Res.
Ocular autoimmunity: the price of privilege?
Immunol. Rev.
Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results
Arch. Ophthalmol.
A look at autoimmunity and inflammation in the eye
J. Clin. Invest.
T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat
J. Immunol.
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens
J. Immunol.
Mouse models of experimental autoimmune uveitis
Ophthalmic Res.
IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma
Invest. Ophthalmol. Vis. Sci.
Cyclosporine-induced alterations of humoral response in experimental autoimmune uveitis
Invest. Ophthalmol. Vis. Sci.
Cited by (262)
The Humira in Ocular Inflammations Taper (HOT) Study
2024, American Journal of OphthalmologyAnterior chamber inflammation grading methods: A critical review
2024, Survey of OphthalmologyArtificial intelligence in uveitis: A comprehensive review
2023, Survey of OphthalmologyAn Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis
2024, Journal of Clinical MedicineOutcomes of pars plana vitrectomy in the management and diagnosis of patients with infectious, non-infectious, and unidentified uveitis
2024, Graefe's Archive for Clinical and Experimental Ophthalmology